Source comparison
Is Tesamorelin Worth It: Clinical vs Compounded Comparison
Understanding the practical differences between branded, FDA-approved tesamorelin and compounded versions is essential when evaluating cost-benefit. Egrifta (branded) $4,000–$6,000 FDA-approved for HIV-associated lipodystrophy High for on-label use, near-zero
This comparison does not assign a generated winner or score.
- Understanding the practical differences between branded, FDA-approved tesamorelin and compounded versions is essential when evaluating cost-benefit.
- Egrifta (branded)
- $4,000–$6,000
- FDA-approved for HIV-associated lipodystrophy
- High for on-label use, near-zero off-label
- Manufactured under full FDA oversight, batch testing, stability data
- Gold standard for documented quality and regulatory compliance. Cost prohibitive without insurance
- Compounded tesamorelin (503B)
- $400–$1,200
- Not FDA-approved as finished product
- Rare. Typically out-of-pocket
- Prepared by registered outsourcing facilities under USP standards, third-party testing varies
- Same active peptide sequence at fraction of cost. Quality depends on facility, no FDA batch oversight
- Research-grade tesamorelin
- Varies by supplier
- Not for human consumption
- Not applicable
- Varies widely. High-purity suppliers provide COA with HPLC and mass spec
- Appropriate only for controlled research. Real Peptides guarantees exact sequencing and purity for laboratory use
- For off-label use, compounded tesamorelin offers the only financially viable access. For FDA-approved indications with insurance authorization, branded Egrifta is the documented standard. Whether tesamorelin worth it off-label almost always hinges on compounded sourcing. The branded cost is unsustainable without coverage.